🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 1 día
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
12/05/2015 0,7900 USD
10/02/2015 0,7900 USD
10/11/2014 0,6100 USD
12/08/2014 0,6100 USD
13/05/2014 0,6100 USD
11/02/2014 0,6100 USD
12/11/2013 0,4700 USD
14/08/2013 0,4700 USD
14/05/2013 0,4700 USD
11/02/2013 0,4700 USD
13/11/2012 0,3600 USD
14/08/2012 0,3600 USD
14/05/2012 0,3600 USD
13/02/2012 0,3600 USD
15/11/2011 0,2800 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/02/2023 236,70 237,86 234,75 237,62 +0,62% 1,31% 2.211.600
22/02/2023 240,30 240,99 235,75 236,16 -0,87% 2,18% 2.187.600
21/02/2023 240,79 241,92 238,20 238,24 -0,95% 1,54% 2.524.100
17/02/2023 235,34 241,72 233,71 240,53 +2,69% 3,40% 2.978.100
16/02/2023 238,46 239,01 234,04 234,22 -2,44% 2,08% 3.291.800
15/02/2023 240,21 240,54 238,73 240,07 -0,40% 0,75% 1.783.300
14/02/2023 242,70 243,00 239,11 241,03 -1,08% 1,60% 2.015.900
13/02/2023 243,20 243,83 241,30 243,66 +0,48% 1,04% 2.321.900
10/02/2023 241,92 244,14 240,41 242,50 +1,04% 1,54% 2.687.200
09/02/2023 241,12 243,46 238,99 240,00 -0,08% 1,85% 3.056.200
08/02/2023 242,99 243,56 239,60 240,20 -1,56% 1,63% 2.761.200
07/02/2023 243,02 244,94 241,42 244,00 +0,06% 1,45% 2.408.000
06/02/2023 245,36 246,80 243,45 243,85 -0,54% 1,37% 2.196.900
03/02/2023 249,96 249,96 242,21 245,17 -0,55% 3,10% 3.073.000
02/02/2023 243,78 246,57 236,37 246,53 +0,05% 4,18% 5.489.100
01/02/2023 249,16 249,55 240,00 246,41 -2,37% 3,83% 5.344.700
31/01/2023 253,86 253,86 249,89 252,40 +0,32% 1,56% 3.418.300
30/01/2023 253,46 254,16 250,60 251,59 -0,81% 1,40% 2.042.800
27/01/2023 254,87 255,50 252,54 253,65 -0,48% 1,16% 2.109.900
26/01/2023 256,54 256,69 253,01 254,88 -0,65% 1,43% 2.522.100
25/01/2023 260,09 261,55 256,02 256,54 -1,22% 2,13% 1.910.600
24/01/2023 261,85 262,00 257,52 259,70 -0,49% 1,71% 1.596.900
23/01/2023 264,00 264,73 259,81 260,97 -0,86% 1,86% 2.025.000
20/01/2023 262,03 263,84 259,87 263,24 +0,46% 1,52% 2.574.100
19/01/2023 262,00 263,52 260,93 262,03 -0,89% 0,99% 2.090.500
18/01/2023 269,42 270,52 263,65 264,39 -1,87% 2,55% 2.218.100
17/01/2023 272,20 273,83 268,83 269,42 -0,85% 1,84% 2.472.800
13/01/2023 270,94 272,23 270,20 271,73 +0,30% 0,75% 1.696.800
12/01/2023 271,92 272,65 268,89 270,92 -0,73% 1,38% 1.454.100
11/01/2023 275,97 276,84 270,18 272,91 -0,35% 2,41% 2.044.400